Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/RedHill Biopharma Ltd./ 20-F

SEC Filing · 20-F

RedHill Biopharma Ltd.

SEC Filing

Filed Apr 28, 2023Accepted Apr 28, 2023, 7:07 AM EDTCIK 1553846Accession 0001558370-23-007149
View company →Permanent SEC source ↗
Share

Company context

We are a specialty biopharmaceutical company, primarily focused on GI, infectious diseases, medical countermeasures and oncology. Our primary goal is to become a leading specialty biopharmaceutical company.

Current securities

RDHLNASDAQ · ADR · Current

Recent company filings

  1. 6-K filingSep 1, 2026
  2. 6-K filingAug 31, 2026
  3. 6-K filingAug 7, 2026
  4. 6-K filingAug 6, 2026
  5. 6-K filingJul 28, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗